Cargando…
Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions
SIMPLE SUMMARY: HER2-low breast cancer (BC) accounts for more than half of breast cancer patients. Anti-HER2 therapy has been ineffective in HER2-low BC, for which palliative chemotherapy is the main treatment modality. The definitive efficacy of T-Dxd in HER2-low BC breaks previous treatment strate...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367369/ https://www.ncbi.nlm.nih.gov/pubmed/35954438 http://dx.doi.org/10.3390/cancers14153774 |